Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Leukemia - 1 May 2026

Vasseur Loïc, Duchmann Matthieu, Duployez Nicolas, Raffoux Emmanuel, Berthon Céline, Heiblig Maël, Genthon Alexis, Braun Thorsten, Leclerc Mathieu, Lebon Delphine, Chantepie Sylvain, Micol Jean-Baptiste, Lambert Juliette, Récher Christian, Chrétien Marie-Lorraine, Iat Alexandre, Vaidie Julien, Malfuson Jean-Valère, Uzunov Madalina, Pigneux Arnaud, Peterlin Pierre, Tarfi Sihem, Hirsch Pierre, Penther Dominique, Jourdan Eric, Celli-Lebras Karine, Preudhomme Claude, Dombret Hervé, Lambert Jérôme, Boissel Nicolas, Itzykson Raphaël

Abstract excerpt

Measurable residual disease (MRD) is a major prognostic factor in Core Binding Factor (CBF) AML. KIT or FLT3 mutations also have prognostic relevance, but little is known about their prognostic value when accounting for MRD. We analyzed the prognostic value of genetic alterations adjusting for early MRD response in adult CBF-AML patients. We grouped data from the retrospective multicenter study RetroCBF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to fms-Like Tyrosine Kinase 3

Share to Multicenter Studies as Topic

Share to Neoplasm, Residual

Share to Observational Studies as Topic

Share to Proto-Oncogene Proteins c-kit

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 41888395
DOI: 10.1038/s41375-026-02900-x

Genes

FLT3
KIT
CBFB
MYH11
RUNX1
RUNX1T1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.PMID 41888395Read ↗

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.Semantic proximity Read ↗

Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.Semantic proximity Read ↗

KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.